Equities | Derivatives | Commodities | Currency | PMS | Depository | Mutual Funds | NBFC | e-Broking



- × (F)

Sector: Animal Feed

### **RESULT REVIEW Q4&FY25**

Declared On: 26 May 2025

# **Ajooni Biotech Limited**

RECOMMENDATION SNAPSHOT									
*CMP	MCap (Rsbn)	Recommendation	Target	Potential Upside					
Rs6	1.01	Hold	Rs9	53%					

<sup>\*</sup>as on 02nd June, 2025

## **About the Company:**

Established in 2010, Ajooni Biotech Limited (ABL) is one of the leading pure veg animal feed, animal healthcare and feed supplements provider dedicated at improving the productivity of dairy farmers with focus on increasing livestock yields. It is involved in the compound, pure veg animal feed and pure veg feed supplements with a portfolio of wide range of quality feed products. Its portfolio has cattle feed, feed chips, camel feed, cotton oilcake, mustard oilcake and wide range of feed supplements to cover the entire life cycle of an animal. ABL is India's first pure veg cattle feed company to have Zero Effect, Zero Defect (ZED) gold process under the Prime Minister Make in India initiative. ABL has built mutually beneficial relationships with esteemed milk societies and milk processing companies. The key customers of the company include IFFCO Kisan, Patanjali, Paras, Mother Dairy, Saahaj, Balinee, Sakhi etc. Mr. Jasjot Singh is the Managing Director and CFO of the company.

# **Results: Quick Glance:**

- The net sales for the quarter reported a growth of 49.5% to Rs293mn as compared to Rs196mn in the same quarter last year
- The Ebitda margins for the quarter under review stood at 3.5% as compared to 8.1% in the comparative quarter last year
- The company reported profit of Rs15mn as compared to Rs9mn in the same quarter last year
- The EPS for the guarter stood at Rs0.09 as compared to Rs0.10 in the corresponding period of last year
- For the full year, the revenues and PAT grew by 43.2% and 56.0% respectively while the Ebitda margins stood at 3.2%

### **Financials:**

Performance (Q4&FY25)										
Q4&FY25 Result (Rs mn)	Mar-25	Mar-24	у-о-у	Dec-24	q-o-q	FY25	FY24	у-о-у	FY26E	
Total Revenue	293	196	49.5%	340	(14.0%)	1147	801	43.2%	1491	
EBITDA	10	16	(36.3%)	9	9.0%	37	22	65.1%	75	
Other Income	13	3	-	4	-	21	22	(5.7%)	21	
Interest	1	1	(48.6%)	1	(16.8%)	3	6	(40.0%)	4	
Depreciation	4	2	59.9%	2	60.4%	11	9	25.1%	11	
Exceptional Items	0	0	-	0	-	0	0	-	0	
Тах	4	6	(36.9%)	3	31.6%	10	8	14.6%	18	
Net Profit	15	9	68.8%	7	-	34	22	56.0%	63	

## **Outlook and Recommendations:**

The company has reported good growth in sales volume as well as tonnage for the quarter under review; however, the bottom line is depressed owing to increased other expenses and higher other income. Generally, the second half of any financial year is meant to be strong for ABL. For what should have been a strong quarter for ABL on the profitable front as well, the company has not been able to report good operational growth; the bottom-line line is propelled by the other income. The company has recently entered the B-2-C market, marking a significant expansion of business scope. ABL is in the process of launching some of its own brands and thus the costs (admin/transport etc.) seems to have increased for the quarter under review. It also appears the company has been focusing only on the segment related to animal feed/fodder rather than the business related to feed supplements which is a slightly higher margin business, the company is making significant strides towards becoming one of the most Research driven products in this sector. ABL has appointed over 300 dealers and distributors across India. To further strengthen this network, the company has formed a high-performance team dedicated to achieve exceptional results. This team is key to driving growth and ensuring long-term success. ABL seems to be running at almost full capacity, and thus has not been able to add any new clients as the Management intends to cater to the demand of the already existing clients.

Please Turn Over Page No 01

Sector: Animal Feed RESULT REVIEW Q4&FY25 Declared On: 26 May 2025

Equities | Derivatives | Commodities | Currency | PMS | Depository | Mutual Funds | NBFC | e-Broking

**Ajooni Biotech Limited** 

## **Outlook and Recommendations (contd.):**

The micro-injection of the new capacity is anticipated to be on stream by Q3FY26. There are some new products in the pipeline, which ABL is yet to launch. With the new capacities which will come online in the next 5-7 months, the company has been busy building its team as well as capabilities. The Management has indicated that the demand for milk and other products has increased from states like Uttar Pradesh which can serve as an opportunity for players like ABL. During the quarter under review, the company participated in two major expos i.e. National Goat Fair and Agro Industrial Exhibition in Uttar Pradesh and National Dairy and Agro Expo at Topriya (Rajasthan). In addition to that, recently the team of ABL was seen in Dairy and Agro expo in Ludhiana and Lucknow, which indicates the intent of the Management to increase the visibility of its brand in key market areas. As the dairy industry in India continues to flourish, the requirement for good quality feed for the same will increase where players like ABL can continue to grow. In order to increase the overall profitability, the company has been putting efforts in backward integration and is in constant talks with the farmers for procurement of RM at a slightly better and cheaper cost. The company is actively undertaking multiple initiatives focused on innovations and sustainability to enhance feed efficiency. ABL is dedicated to improve the productivity of dairy farmers and sustainably increase the livestock yield. During the year under review, the company deferred the fundraising via warrants owing to geo-political issues and lack of interest by investors. The initiatives related to the Moringa plantation are still in the early stage of development where a lot of growth triggers will depend on the directives as per the government. The ongoing field trials of Moringa are also taking shape but at a very slow pace; however, once it is successful then the company can show immense growth as a flag bearer in the cattle feed sector. Considering the slight delay in the execution of some of the projects and its time for delivery which can impact the margins going forward, we have reduced our target price to Rs9.

#### **DISCLAIMERS AND DISCLOSURES-**

Progressive Share Brokers Pvt. Ltd. and its affiliates are a full-service, brokerage and financing group. Progressive Share Brokers Pvt. Ltd. (PSBPL) along with its affiliates are participants in virtually all securities trading markets in India. PSBPL started its operation on the National Stock Exchange (NSE) in 1996. PSBPL is a corporate trading member of Bombay Stock Exchange Limited (BSE), National Stock Exchange of India Limited (NSE) for its stock broking services and is Depository Participant with Central Depository Services Limited (CDSL) and is a member of Association of Mutual Funds of India (AMFI) for distribution of financial products.

PSBPL is SEBI registered Research Analyst under SEBI (Research Analysts) Regulations, 2014 with SEBI Registration No. INH000000859/Research Analyst BSE Enlistment No. 5049. PSBPL hereby declares that it has not defaulted with any stock exchange nor its activities were suspended by any stock exchange with whom it is registered in last five years. PSBPL has not been debarred from doing business by any Stock Exchange/SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

PSBPL offers research services to clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

Other disclosures by Progressive Share Brokers Pvt. Ltd. (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company (s) covered in this report-:

- · PSBPL or its associates financial interest in the subject company: NO
- · Research Analyst (s) or his/her relative's financial interest in the subject company: NO
- · PSBPL or its associates and Research Analyst or his/her relative's does not have any material conflict of interest in the subject company. The research Analyst or research entity (PSBPL) has not been engaged in market making activity for the subject company.
- · PSBPL or its associates actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report: NO
- · Research Analyst or his/her relatives have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report: NO
- · PSBPL or its associates may have received any compensation including for brokerage services from the subject company in the past 12 months. PSBPL or its associates may have received compensation for products or services other than brokerage services from the subject company in the past 12 months. PSBPL or its associates have not received any compensation or other benefits from the Subject Company or third party in connection with the research report. Subject Company may have been client of PSBPL or its associates during twelve months preceding the date of distribution of the research report and PSBPL may have co-managed public offering of securities for the subject company in the past twelve months.
- $\cdot \, \text{The research analyst has served as officer, director or employee of the subject company: NO} \\$
- Registration granted by SEBI and certification from NISM is in no way guarantee performance of the intermediary or provide any assurance of returns to investors

PSBPL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. Our sales people, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses (if any) may make investment decisions that may be inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution publication, availability or use would be contrary to law or regulation or which would subject PSBPL or its group companies to any registration or licensing requirement within such jurisdiction. If this document is sent or has reached any individual in such country, especially, USA, the same may be ignored. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of PSBPL. All trademarks, service marks and logos used in this report are trademarks or registered trademarks of PSBPL or its Group Companies. The information contained herein is not intended for publication or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is pr

#### Terms & Conditions:

This report has been prepared by PSBPL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of PSBPL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and its at the discretion of the clients to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. PSBPL will not treat recipients as customers by virtue of their receiving this report.

#### Registered Office Address:

Progressive Share Brokers Pvt. Ltd,

122-124, Laxmi Plaza, Laxmi Indl Estate,

New Link Rd, Andheri West,

Mumbai—400053, Maharashtra

www.progressiveshares.com | Contact No.:022-40777500.

#### Compliance Officer:

Ms. Neha Oza,

Email: compliance @progressive shares.com,

Contact No.:022-40777500.

Grievance Officer:

Email: grievance cell@progressive shares.com